表紙
市場調查報告書

骨質疏鬆症治療藥的全球市場:2019年∼2023年

Global Osteoporosis Drugs Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 295852
出版日期 內容資訊 英文 122 Pages
訂單完成後即時交付
價格
骨質疏鬆症治療藥的全球市場:2019年∼2023年 Global Osteoporosis Drugs Market 2019-2023
出版日期: 2019年03月12日內容資訊: 英文 122 Pages
簡介

骨質疏鬆症患者的償付計劃的可用性將推動預測期內的市場成長。骨質疏鬆症是老年人群中最普遍的。因此,美國、德國、日本、英國、法國、加拿大、西班牙和其他發展歐洲國家等主要市場提供償付計劃。Technavio的分析師預測,到2023年,骨質疏鬆症藥物市場的年複合成長率將接近5%。

本報告提供全球骨質疏鬆症治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 報告的範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 骨吸收抑制劑
  • 同化劑
  • 市場機會:各產品

第7章 客戶形勢

第8章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 市場趨勢

第12章 業者情勢

  • 概要
  • 創造性破壞狀況

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Amgen Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc.
  • Radius Health, Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31009

About this market

The availability of reimbursement programs for patients with osteoporosis will drive the market growth during the forecast period. Osteoporosis is the most prevalent among the geriatric population. Therefore, major markets such as the US, Germany, Japan, the UK, France, Canada, Spain, and other developed European countries are providing reimbursement schemes. Technavio's analysts have predicted that the osteoporosis drugs market will register a CAGR of almost 5% by 2023.

Market Overview

Increasing prevalence of osteoporosis

Osteoporosis prevalence has increased worldwide due to which it is considered a serious public health concern. Osteoporosis is more common in older women than in older men. The improved standards of healthcare facilities and sophisticated treatment options have increased the life expectancy rates, augmenting the aging population

Side effects of osteoporosis drugs

Side effects of bisphosphonates such as alendronate, ibandronate, risedronate, and zoledronic acid may include muscle pain, joint pain, nausea, difficulty swallowing, heartburn, irritation of the esophagus, and gastric ulcers. Also, these drugs can cause osteonecrosis of the jaw. The risk of osteonecrosis of the jaw in an individual increase with treatment periods longer than 5 years.

For the detailed list of factors that will drive and challenge the growth of the osteoporosis drugs market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Antiresorptive drugs - Market size and forecast 2018-2023
  • Anabolic drugs - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Market trends

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc.
  • Radius Health, Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global metabolic disorder therapeutics market
  • Exhibit 02: Segments of global metabolic disorder therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: Antiresorptive drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Antiresorptive drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Anabolic drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Anabolic drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Market opportunity by product
  • Exhibit 24: Customer landscape
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Key leading countries
  • Exhibit 36: Market opportunity
  • Exhibit 37: Late-stage pipeline drugs for osteoporosis
  • Exhibit 38: Patent expiry of osteoporosis drugs
  • Exhibit 39: Impact of drivers and challenges
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: Amgen Inc. - Vendor overview
  • Exhibit 46: Amgen Inc. - Business segments
  • Exhibit 47: Amgen Inc. - Organizational developments
  • Exhibit 48: Amgen Inc. - Geographic focus
  • Exhibit 49: Amgen Inc. - Key offerings
  • Exhibit 50: Eli Lilly and Company - Vendor overview
  • Exhibit 51: Eli Lilly and Company - Business segments
  • Exhibit 52: Eli Lilly and Company - Organizational developments
  • Exhibit 53: Eli Lilly and Company - Geographic focus
  • Exhibit 54: Eli Lilly and Company - Segment focus
  • Exhibit 55: Eli Lilly and Company - Key offerings
  • Exhibit 56: Novartis AG - Vendor overview
  • Exhibit 57: Novartis AG - Business segments
  • Exhibit 58: Novartis AG - Organizational developments
  • Exhibit 59: Novartis AG - Geographic focus
  • Exhibit 60: Novartis AG - Segment focus
  • Exhibit 61: Novartis AG - Key offerings
  • Exhibit 62: Pfizer Inc. - Vendor overview
  • Exhibit 63: Pfizer Inc. - Business segments
  • Exhibit 64: Pfizer Inc. - Organizational developments
  • Exhibit 65: Pfizer Inc. - Geographic focus
  • Exhibit 66: Pfizer Inc. - Segment focus
  • Exhibit 67: Pfizer Inc. - Key offerings
  • Exhibit 68: Radius Health, Inc. - Vendor overview
  • Exhibit 69: Radius Health, Inc. - Organizational developments
  • Exhibit 70: Radius Health, Inc. - Key offerings
  • Exhibit 71: Validation techniques employed for market sizing